Shares of Teleflex Inc. TFX advanced 1.05% to $137.71 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 2.13% to 5,638.94 and ...

Teleflex's (NYSE: TFX) fourth-quarter 2024 earnings conference call, held on February 27, 2025, revealed significant ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $158.75, ...

Teleflex is splitting its business into two independently traded entities, with a completion date set for mid-2026 ...

Teleflex is separating into two publicly traded companies to optimize growth and shareholder value. The acquisition of Biotronik's Vascular Intervention expands Teleflex's presence in coronary and ...

Acquisition will further advance Teleflex’s Interventional portfolio with a differentiated global suite of coronary vascular and peripheral vascular intervention devicesWAYNE, Pa., Feb. 27, 2025 ...

Teleflex (NYSE: TFX) announced today that it plans to separate its Urology, Acute Care and OEM businesses into a new publicly traded company.

Teleflex plans to split into two companies by mid-2026, with RemainCo focusing on high-growth hospital markets and NewCo on urology and OEM. Teleflex will acquire Biotronik's Vascular Intervention ...

Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak ...

Teleflex, whose shares sank nearly 20% Thursday, will acquire most of Biotronik’s vascular intervention assets. Teleflex also ...

NEW YORK, NY / ACCESS Newswire / March 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex ...